Stock ILM1 MEDIOS AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Medios AG

Equities

ILM1

DE000A1MMCC8

Market Closed - Xetra
Other stock markets
 11:36:17 2024-05-03 am EDT 		After market 03:58:01 pm
13.98 EUR +0.43% Intraday chart for Medios AG 14.14 +1.14%
Mar. 27 Medios AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 18 Medios AG Provides Earnings Guidance for the Year 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • With a P/E ratio at 11.7 for the current year and 10.21 for next year, earnings multiples are highly attractive compared with competitors.
  • The stock, which is currently worth 2024 to 0.25 times its sales, is clearly overvalued in comparison with peers.
  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MEDIOS AG Stock Medios AG
-11.85% 355M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ILM1 Stock
  4. Ratings Medios AG